{"slug":"ara-290","title":"ARA-290 (Cibinetide)","body":"ARA-290, also called cibinetide, is an 11-amino-acid peptide cut from a single face of the erythropoietin molecule. It keeps EPO's tissue-repair signal and throws away EPO's blood-building one — and that split is the entire point of the drug. It is the rarest and, in one specific way, the best-evidenced compound in a disc-recovery stack: unlike the others, it has randomized, placebo-controlled human trials, and some of that data shows nerves physically regrowing. It is also the hardest to actually obtain, and its developer has effectively gone dark. This page covers the mechanism, the human and preclinical evidence graded honestly, the exact trial dosing, the safety story (which is EPO's story inverted), the sourcing reality, and precisely where it fits for the nerve pain of a damaged disc. No prior knowledge assumed.\n\n## Erythropoietin, minus the blood\n\nEPO is famous for telling the marrow to make red blood cells, and infamous for the clots and strokes that follow when athletes abuse it. But EPO does something else at a site of injury: it protects and repairs stressed tissue. The problem is you cannot dose EPO for repair without also thickening the blood and taking on that risk.\n\nMichael Brines and Anthony Cerami worked out why the two effects separate. EPO's repair signal runs through a different receptor than its blood signal — a heterocomplex of the EPO receptor joined to the beta-common receptor, which they named the innate repair receptor.\n\n[[embed:source:s8]]\n\nOnce repair was known to run through a distinct receptor, they built small peptides mimicking only the repair-active face of EPO. ARA-290 is that idea shipped as an 11-amino-acid drug.\n\n[[embed:source:s9]]\n\n## The receptor that only shows up when tissue is hurt\n\nThe innate repair receptor is not sitting on healthy cells. It is upregulated on injured and inflamed tissue — so ARA-290 acts where there is damage and stays quiet where there isn't. Its job there is anti-inflammatory and pro-survival: it tells macrophages to stand down and keeps stressed cells alive.\n\n[[embed:source:s6]]\n\n## It regrows nerve fibers — measured, not felt\n\nThis is what separates ARA-290 from nearly everything else marketed as a healing peptide. In a Phase 2b randomized controlled trial in 64 patients with sarcoidosis-associated small-fiber neuropathy, 4 mg/day cibinetide significantly increased corneal nerve fiber area — an objective, imaged measure — and raised GAP-43-positive regenerating fibers in the skin. GAP-43 marks nerves actively growing back.\n\n[[embed:source:s3]]\n\nAn earlier randomized, double-blind pilot had already shown the symptom side: significantly better neuropathy scores versus placebo by week four.\n\n[[embed:source:s1]]\n\nThe independent read was blunt: it regenerates nerve fibers.\n\n[[embed:source:s12]]\n\n## It calms the nerve, not just the symptom\n\nThis is why it matters for a disc. Radicular pain — sciatica — is not only mechanical; when nucleus pulposus contacts a nerve root it sets off neuroinflammation, much of it driven by activated microglia in the spinal cord. In nerve-injury models, ARA-290 produced long-lasting, dose-dependent reductions in allodynia that tracked with suppression of exactly that spinal microglial response.\n\n[[embed:source:s5]]\n\nSo the mechanism is not \"mask the pain for a few hours.\" It is \"quiet the central inflammation generating the pain\" — a more durable kind of relief, aimed at the specific way a herniated disc hurts.\n\n## The benefit generalizes past nerves\n\nThe repair signal is not nerve-specific. The same peptide class is anti-apoptotic and tissue-protective in the heart.\n\n[[embed:source:s7]]\n\nAnd a second human population — type 2 diabetics — showed improved neuropathic symptoms alongside better HbA1c and lipids over 56 days, with no safety signal.\n\n[[embed:source:s4]]\n\nTwo independent human neuropathy datasets plus organ-level tissue protection in the lab is a stronger evidence base than most peptides in this category can claim.\n\n## How it's dosed\n\nThe human trials are specific and consistent, which is unusual here.\n\n- **Dose:** 4 mg subcutaneously, once daily, is the effective and consensus clinical dose. The dose-ranging trial tested 1, 4, and 8 mg; 4 mg was the sweet spot.\n- **Duration:** trials ran 28 days, with follow-up out to weeks; symptom and structural nerve changes were measurable by day 28.\n- **The half-life paradox:** ARA-290 clears the blood in minutes, yet is dosed once daily and works. It triggers a downstream repair program rather than needing sustained blood levels, so the effect outlasts the drug by 24-72 hours. This is why a minutes-long half-life and once-daily dosing are not a contradiction.\n\n## The safety story is EPO's, inverted\n\nThe single most important safety fact: because ARA-290 works through the innate repair receptor and not the classic EPO receptor, it does not stimulate red-cell production or raise hematocrit — confirmed in the trials, with no change in hemoglobin, hematocrit, or reticulocytes.\n\n[[embed:source:s11]]\n\nThat removes the clotting hazard that makes EPO dangerous and is the reason chronic dosing for repair is even conceivable. Across the Phase 2 trials the only adverse events were mild, transient injection-site reactions; no serious drug-related events. The honest limit: total human exposure is small (under ~200 patients, all ≤28 days), so long-term safety is uncharacterized, and as an innate-repair-receptor agonist it should be treated cautiously in active malignancy.\n\n## You probably can't get the real thing\n\nThis is the practical catch. ARA-290 was developed by Araim Pharmaceuticals, earned FDA Orphan Drug and Fast Track designations for sarcoidosis neuropathic pain plus EU orphan status, met its Phase 2b endpoint — and then stalled. No Phase 3 was completed, it is not approved for anything, and as of 2026 Araim has effectively ceased operations with no active trials registered. So there is no pharmaceutical supply. On the grey market it is far rarer and costlier than BPC-157 or TB-500, carried by few vendors intermittently, which means less independent testing and higher odds of an underdosed or degraded 11-amino-acid peptide. If someone sources it, a third-party HPLC-plus-mass-spec certificate per batch is non-negotiable.\n\n## What people report\n\nControlled trials are the evidence; user accounts are color. One first-person write-up describes going from weeks of stabbing nerve pain to none on ARA-290.\n\n[[embed:source:s13]]\n\nA single uncontrolled anecdote, weighed far below the randomized data — but it rhymes with what the trials measured.\n\n## Where it fits for the spine\n\nIn a disc-recovery stack the division of labor is clean. BPC-157 and TB-500 target the tissue — annulus, ligament, surrounding soft tissue. Retatrutide targets mechanical load. ARA-290 targets the nerve: it is the arm for the neuroinflammatory, radicular pain of a herniation, and the only one of the four with human evidence of actual nerve regeneration. The inflamed nerve root of a herniated disc is, mechanistically, exactly the small-fiber, neuroinflammatory target ARA-290 was built for — even though no one has run it against discs. The framework is in the disc-stack, herniated-disc, and degenerative-disc-disease pages.\n\n## Proven, unproven, unknown\n\nProven in humans: ARA-290 reduces neuropathic-pain symptoms and increases measurable nerve-fiber regrowth in sarcoidosis small-fiber neuropathy, and improves diabetic neuropathic symptoms — in randomized, placebo-controlled trials, without raising hematocrit. Unproven: that this translates to the radicular pain of a herniated disc; that step is mechanistic reasoning plus adjacent trial data, not a disc trial. Unknown: long-term safety, and — practically — whether the vial you can actually buy contains the real peptide.\n\n*Not medical advice. ARA-290 is investigational, not approved for any condition, and has no pharmaceutical supply. Nothing here is a dosing or treatment recommendation.*\n","register":"essay","tags":["peptide","ara-290","cibinetide","neuropathy","disc"],"style":{},"claims":[{"id":"c1","text":"ARA-290 (cibinetide) is an 11-amino-acid peptide from EPO's helix-B surface that activates the innate repair receptor (EPOR/beta-common heterocomplex) to drive tissue repair, distinct from EPO's erythropoietic receptor.","tier":"mechanistic","source_ids":["s8","s9","s11"],"why_material":"Core mechanism separating repair signaling from blood effects."},{"id":"c2","text":"Because it engages the innate repair receptor rather than the homodimeric EPO receptor, ARA-290 does not stimulate erythropoiesis or raise hematocrit, avoiding EPO's thrombotic risk.","tier":"mechanistic","source_ids":["s11","s4"],"why_material":"The key safety differentiator from EPO."},{"id":"c3","text":"The mechanism was defined by Michael Brines and Anthony Cerami, who showed EPO's tissue protection runs through an EPOR/beta-common-receptor heterocomplex.","tier":"mechanistic","source_ids":["s8","s9"],"why_material":"Scientific provenance for the IRR framework."},{"id":"c4","text":"In a randomized, double-blind, placebo-controlled pilot in sarcoidosis patients with small-fiber neuropathy, ARA 290 significantly improved neuropathy symptom scores versus placebo.","tier":"human","source_ids":["s1"],"why_material":"First controlled human evidence ARA-290 reduces neuropathic-pain symptoms."},{"id":"c5","text":"In a Phase 2b RCT (n=64), 4 mg/day cibinetide significantly increased corneal nerve fiber area and raised GAP-43+ regenerating intraepidermal nerve fibers, an objective structural sign of nerve regeneration.","tier":"human","source_ids":["s3","s2","s12"],"why_material":"Strongest human evidence for actual nerve regeneration, not symptom masking."},{"id":"c6","text":"In type 2 diabetics, ARA 290 improved neuropathic symptoms alongside HbA1c and lipids over 56 days without safety issues.","tier":"human","source_ids":["s4"],"why_material":"Second independent human neuropathy dataset."},{"id":"c7","text":"In nerve-injury models, ARA 290 produced long-lasting, dose-dependent reductions in allodynia coupled to suppression of the spinal microglial neuroinflammatory response.","tier":"preclinical","source_ids":["s5"],"why_material":"Supports the neuroinflammatory-pain thesis for radicular pain."},{"id":"c8","text":"ARA 290 inhibits macrophage activation and pro-inflammatory cytokine release (IL-6, IL-12, TNF-alpha) and protects cells from cytokine-induced apoptosis.","tier":"preclinical","source_ids":["s6"],"why_material":"Anti-inflammatory basis for an inflamed degenerative-disc environment."},{"id":"c9","text":"The helix-B-surface peptide class (ARA-290) is anti-apoptotic and tissue-protective across organs, including the heart, indicating a general repair mechanism.","tier":"preclinical","source_ids":["s7","s9"],"why_material":"Generalizes the repair mechanism."},{"id":"c10","text":"Uncontrolled first-person reports describe rapid relief of stabbing nerve pain on ARA-290, consistent with but far weaker than the controlled trial data.","tier":"anecdotal","source_ids":["s13"],"why_material":"Real-world color, explicitly flagged as anecdotal."}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/23168581/","title":"Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study","quote":"The ARA 290 group showed significant (p < 0.05) improvement at wk 4 in SFNSL score compared with placebo","claim_ids":["c4"]},{"id":"s2","type":"pubmed","url":"https://clinicaltrials.gov/study/NCT02039687","title":"Phase 2 Dose Ranging Study of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms in Sarcoidosis","quote":"activate repair mechanisms and accelerate healing, including the nerve damage that can be associated with sarcoidosis","claim_ids":["c5"]},{"id":"s3","type":"pubmed","url":"https://research.manchester.ac.uk/en/publications/cibinetide-improves-corneal-nerve-fiber-abundance-in-patients-wit/","title":"Cibinetide improves corneal nerve fiber abundance in patients with sarcoidosis-associated small nerve fiber loss and neuropathic pain","quote":"The placebo-corrected mean change from baseline CNFA at day 28 was 697 (159, 1236; P = 0.012)","claim_ids":["c5"]},{"id":"s4","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/25387363/","title":"ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes","quote":"Subjects receiving ARA 290 exhibited an improvement in hemoglobin A1c and lipid profiles throughout the 56 d observation period.","claim_ids":["c6"]},{"id":"s5","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC3928087/","title":"ARA 290 produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response","quote":"ARA290 dose-dependently reduced allodynia coupled to suppression of the spinal microglia response","claim_ids":["c7"]},{"id":"s6","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/26683514/","title":"A Nonhematopoietic Erythropoietin Analogue, ARA 290, Inhibits Macrophage Activation and Prevents Damage to Transplanted Islets","quote":"Secretion of pro-inflammatory cytokines (IL-6, IL-12, and TNF-alpha) from macrophages was significantly inhibited by ARA 290.","claim_ids":["c8"]},{"id":"s7","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/20660739/","title":"Cardioprotection by a nonerythropoietic, tissue-protective peptide mimicking the 3D structure of erythropoietin","quote":"HBSP protects cardiomyocytes from apoptosis and leads to a favorable outcome in failing hearts","claim_ids":["c9"]},{"id":"s8","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/15456912/","title":"Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor","quote":"EpoR and betacR comprise a tissue-protective heteroreceptor.","claim_ids":["c1","c3"]},{"id":"s9","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/18676614/","title":"Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin","quote":"the tissue-protective activities of EPO are mimicked by small, nonerythropoietic peptides that simulate a portion of EPO's three-dimensional structure.","claim_ids":["c1","c3"]},{"id":"s11","type":"news","url":"https://superpower.com/guides/ara-290","title":"ARA-290 (Cibinetide): An EPO-Derived 11-Amino-Acid Peptide Targeting the Innate Repair Receptor","quote":"not stimulate erythropoiesis or raise red blood cell counts","claim_ids":["c2"]},{"id":"s12","type":"news","url":"https://sarcoidosisnews.com/news/cibinetide-seems-to-regenerate-nerve-fibers-improve-pain-in-sarcoidosis-patients/","title":"Cibinetide Seems to Regenerate Nerve Fibers, Improve Pain in Sarcoidosis Patients","quote":"cibinetide (ARA 290) was shown to promote significant corneal nerve and improve pain and functional capacity in a clinical trial with sarcoidosis patients.","claim_ids":["c5"]},{"id":"s13","type":"news","url":"https://diaryofrecovery.com/ara/","title":"ARA 290 for Nerve Pain & Regeneration (first-person account)","quote":"I went from 3 weeks of being unable to put on pants or get in the car without stabbing pain, to zero pain.","claim_ids":["c10"]},{"id":"s14","type":"news","url":"https://www.prnewswire.com/news-releases/araim-pharmaceuticals-receives-orphan-drug-designation-from-the-us-fda-for-ara-290-for-the-treatment-of-sarcoidosis-300293773.html","title":"Araim Pharmaceuticals Receives FDA Orphan Drug Designation for ARA 290 (sarcoidosis)","quote":"Orphan Drug Designation from the US FDA for ARA 290 for the Treatment of Sarcoidosis","claim_ids":[]}],"prov":{"model":"Fable 5 (Claude Code)","action":"write"}}